Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies.
about
System vaccinology for the evaluation of influenza vaccine safety by multiplex gene detection of novel biomarkers in a preclinical study and batch release test.Archaeosomes made of Halorubrum tebenquichense total polar lipids: a new source of adjuvancy.Nonclinical vaccine safety evaluation: advantages of continuous temperature monitoring using abdominally implanted data loggers.Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvantNew adjuvants: EU regulatory developments.Pre-clinical toxicity & immunobiological evaluation of DNA rabies vaccine & combination rabies vaccine in rhesus monkeys (Macaca mulatta).From discovery to licensure, the Adjuvant System story.Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?Current adjuvants and new perspectives in vaccine formulation.What can economics add to health technology assessment? Please not just another cost-effectiveness analysis!The Hen's Egg Test on Chorioallantoic Membrane: An Alternative Assay for the Assessment of the Irritating Effect of Vaccine Adjuvants.A safety and immunogenicity study of a novel subunit plague vaccine in cynomolgus macaques.Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform.
P2860
Q30364552-5BCF1449-C01F-40B8-B880-EFAA65E0A6E4Q33493219-726F1437-6BF2-4E0B-B7C4-3BDEED0D9061Q34191062-057A9EA6-59D7-4ABE-9BB5-BADE05C94932Q34705057-61FF2A6F-941D-4B79-B362-A8AFF54D0A2BQ35080697-4AE621BA-65C2-4B5F-82DD-FB3B13B2337EQ36968305-319463CB-0A63-464E-BB2D-3C731BFA2662Q37073211-68D0B8B4-3A69-4DB8-BADC-CE7776FD4873Q37619140-5B6A156C-ACF1-452E-BA9E-AB1FF6F036B9Q37800934-A36194AF-6E63-438E-8172-F958CDAE6741Q37909424-05811AA3-BA1F-4E90-9F27-0B780B4773C0Q38921107-4F7EE3BA-8541-45E6-9343-EB7B7D63D753Q39298187-63419A51-16E3-4579-A30D-34B86AAF5D7EQ48309869-506D0BDD-FB6D-489E-BFC7-0761D665AD92Q48316344-89B0DFB9-A803-4998-B9A8-42633B92E833
P2860
Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Non-clinical safety evaluation ...... new products, new strategies.
@ast
Non-clinical safety evaluation ...... new products, new strategies.
@en
type
label
Non-clinical safety evaluation ...... new products, new strategies.
@ast
Non-clinical safety evaluation ...... new products, new strategies.
@en
prefLabel
Non-clinical safety evaluation ...... new products, new strategies.
@ast
Non-clinical safety evaluation ...... new products, new strategies.
@en
P1433
P1476
Non-clinical safety evaluation ...... new products, new strategies.
@en
P2093
Frank R Brennan
Gordon Dougan
P304
P356
10.1016/J.VACCINE.2004.11.072
P407
P577
2005-05-01T00:00:00Z